A Monthly TB Lab Quality Indicator Dashboard for Managers
A monthly quality indicator dashboard is one of the most practical tools a tuberculosis laboratory manager can build. It brings together the most important signals from microscopy, culture, molecular, and drug susceptibility workflows into a single view that is reviewed on a fixed date each month. For managers supervising teams across multiple sites, the dashboard makes it possible to spot a creeping turnaround-time delay in Brisbane before it affects the state reference hospital, or to see that MGIT positivity rates in Perth have drifted from the expected pattern.
The work of building one does not need to be expensive or complex. A well-designed Excel workbook, a SharePoint list, or a Power BI report connected to the laboratory information system will serve most Australian TB facilities. What matters is that the indicators chosen are genuinely meaningful, that the data feeding them is reliable, and that the monthly review is treated as a working meeting rather than a formality. The four-phase structure of the GLI Quality Tool offers a natural scaffold for the work, and the practical guidance below shows how a manager can move from a blank page to a functioning dashboard within a single quarter.
Selecting Indicators That Reflect Real TB Testing Performance
The first decision is which indicators deserve a place on the dashboard. A common mistake is to add everything the laboratory measures, which creates visual noise and dilutes attention. A focused set of eight to twelve indicators, grouped under the twelve Quality Systems Essentials, is far more useful for a monthly review.
For a TB laboratory in Australia, the core testing indicators usually include turnaround time from sample receipt to result for smear microscopy, MGIT culture, Xpert MTB/RIF or Xpert Ultra, and first-line line-probe assay. Sample rejection rates, contamination rates for liquid culture, and the proportion of culture-positive samples confirmed by molecular methods are equally important. Beyond testing, the manager should consider indicators for biosafety, equipment uptime, stock consumption, staff training, and internal audit findings.
The local environment shapes priorities. Reference laboratories in Sydney's ICPMR network, Melbourne's VIDRL, and Brisbane's Queensland Health Forensic and Scientific Services typically work to tight state health department turnaround expectations, and those contracts often specify indicator definitions. Regional centres in Darwin, Hobart, or regional Western Australia may be more concerned with sample transport times from remote clinics, where the wet season regularly disrupts flights into remote communities.
Defining Targets, Thresholds, and Data Sources
Each indicator needs a target, a yellow threshold, and a red threshold, expressed in figures that the team understands and can influence. A target such as "≥90% of smear results within 24 hours of receipt" is useful only if the laboratory has a clear baseline and the data capture is consistent. Setting targets should be a consultative exercise with bench scientists, because the people closest to the workflow are usually the first to notice when a target is unrealistic.
A simple example set for a metropolitan reference laboratory might look like this:
| Indicator | Green | Amber | Red | Source |
|---|---|---|---|---|
| Smear microscopy TAT (≤24h) | ≥90% | 80–89% | <80% | LIS |
| MGIT culture TAT (≤42d) | ≥85% | 75–84% | <75% | LIS |
| Xpert Ultra invalid rate | ≤2% | 3–4% | >4% | LIS |
| Liquid culture contamination | ≤8% | 9–12% | >12% | Worksheet |
| Sample rejection rate | ≤3% | 4–6% | >6% | Reception log |
| Equipment unplanned downtime | ≤2% | 3–5% | >5% | Asset register |
Australian laboratories also need to align targets with accreditation requirements. NATA accreditation against ISO 15189, and the NPAAC standards that underpin it, expect laboratories to demonstrate quality indicators that are monitored, trended, and acted upon. Where state health departments fund TB testing, performance agreements may set additional turnaround or reporting requirements, and the dashboard should reflect those contractual obligations.
Budget pressure is a recurring reality, particularly for public laboratories outside the metropolitan reference networks. Equipment downtime can quietly erode capacity when maintenance contracts are deferred, and a dashboard that records both planned and unplanned downtime is often the prompt for difficult conversations about equipment maintenance budgets. Linking the indicator to a documented response plan turns a chart into a management tool.
Building the Dashboard Structure for Quick Monthly Review
Layout matters because the dashboard is reviewed under time pressure. A one-page summary up front, with traffic-light status for each indicator and a short narrative explaining any red or amber entries, is far more effective than a multi-tab workbook that requires drilling. A second page can hold trend charts showing the previous twelve months, and a third page can list the corrective actions carried over from previous reviews.
Visual choices should be deliberate. Run charts are better than bar graphs for indicators tracked over time, because they make step changes visible. Pie charts are rarely useful. Where state health departments publish aggregate data, benchmarking against the state average can add context, although care is needed to ensure definitions match.
Biosafety and emergency preparedness are sometimes left off the dashboard, but they belong there. A small section tracking the completion of safety drills ensures that this work is visible to senior management and not crowded out by testing throughput. The same approach works for chemical and biological spills, needle-stick follow-up, and biosafety cabinet certifications.
Validating Data and Reconciling With External Reports
A dashboard is only as trustworthy as its data. Before each monthly review, the person compiling the report should reconcile the figures with the laboratory information system, the state health department notification register, and any external quality assurance returns. Discrepancies are common at the boundaries between systems, particularly when samples are referred from one state to another or when a private pathology provider (such as those operated by Sonic Healthcare or Healius) handles the initial screening.
Validation should be a standing agenda item, not an afterthought. Where the National Reference Laboratory or the WHO Supranational Reference Laboratory network returns a proficiency testing result that differs from the laboratory's own report, the discrepancy itself becomes an indicator. The same applies to culture contamination rates when a new batch of MGIT bottles is introduced, or to Xpert error rates after a software update.
Reconciling with the National Notifiable Diseases Surveillance System adds another layer of assurance, because TB is a nationally notifiable condition and every positive result should be captured in both the laboratory record and the jurisdictional notification. The monthly review is a good moment to confirm that the two systems agree.
Turning Monthly Review Meetings into Corrective Action
The review meeting should follow a fixed agenda: review of last month's actions, walk through each indicator, accept the explanations offered, and assign new actions. Attendance should include the laboratory manager, a senior scientist, a quality officer, and a representative from the clinical or public health side, particularly where turnaround times affect contact tracing.
Minutes matter. Decisions taken verbally in the meeting rarely lead to change unless they are recorded with an owner and a due date. A practical corrective action log becomes the memory of the dashboard, ensuring that a contamination spike in March is not relitigated in July as though it were new.
The social dynamics of these meetings are worth attention. Senior staff in Australian public laboratories are often reluctant to flag problems in front of management, particularly where understaffing or budget constraints are the underlying cause. Framing the review as a learning exercise, with a rotating chair, helps distribute accountability and keeps the conversation focused on systems rather than individuals.
Embedding the Dashboard in Accreditation and Surveillance Cycles
The monthly dashboard is most valuable when it connects to the wider quality cycle. Quarterly management reviews, annual internal audits, and NATA surveillance assessments all draw on the same evidence base, and a well-kept dashboard saves hours of preparation. The data also feeds into state-level TB program reporting required by the Commonwealth through the National Tuberculosis Advisory Committee, which provides independent advice to the Australian Government Department of Health.
A useful discipline is to align the financial year. Australian public laboratories operate against state budget cycles, and a dashboard whose review meetings sit comfortably inside the quarterly reporting rhythm is easier to sustain. Linking the dashboard to the laboratory's strategic plan, and to the GLI Quality Tool's twelve Quality Systems Essentials, makes the case for resourcing when competing priorities arise.
For managers who are starting from scratch, the most practical first step is to pick six indicators, set realistic thresholds, and review them monthly for two quarters before adding more. The discipline of the monthly review, more than the sophistication of the chart, is what drives improvement.
Begin with the phase-specific checklists inside the GLI Quality Tool, and use the four-phase roadmap to schedule the introduction of each indicator. Pair the dashboard rollout with a written data-governance note, agree the review meeting date for the next twelve months, and invite a clinical colleague to the first session so the conversation starts on the right foot. A working dashboard, reviewed faithfully, will shape TB laboratory quality across the year more than any single audit ever could.